SGLT-2 inhibitor associated euglycaemic diabetic ketoacidosis in an orthopaedic trauma patient

Duncan Taylor Ritchie* (Corresponding Author), James Dixon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Euglycaemic diabetic ketoacidosis is a serious but rare adverse effect of treatment with sodium-glucose cotransporter-2 (SGLT-2) inhibitors. A man in his 60s with type 2 diabetes mellitus underwent total hip replacement for an intracapsular neck of femur fracture. His SGLT-2 inhibitor was continued perioperatively and blood glucose levels were normal throughout the admission. A diagnosis of severe euglycaemic diabetic ketoacidosis was made in the operating theatre which required treatment in a critical care unit. This resulted in increased morbidity due to decreased postoperative mobilisation and a new requirement for subcutaneous insulin. This case highlights the need for withholding SGLT-2 inhibitors in patients admitted for emergency surgery and a need for regular ketone monitoring in these patients, even in the context of normoglycaemia.
Original languageEnglish
Article numbere250233
JournalBMJ Case Reports
Volume15
Issue number9
Early online date16 Sept 2022
DOIs
Publication statusPublished - Sept 2022
Externally publishedYes

Fingerprint

Dive into the research topics of 'SGLT-2 inhibitor associated euglycaemic diabetic ketoacidosis in an orthopaedic trauma patient'. Together they form a unique fingerprint.

Cite this